No Drug Has Ever Cured This $560B Disease. This Biotech Believes They've Made One.

This is sponsored content. Barchart is not endorsing the websites or products set forth below.

There are few chronic diseases more common worldwide than arthritis. And osteoarthritis, the most prevalent form, has no cure.

Over 500 million people globally suffer from the disease, fueling a $560B market. Every available treatment just masks the pain while cartilage continues to deteriorate. Big Pharma has poured over $1 billion into finding a real solution, but every single attempt has failed because there are multiple culprits attacking joints all at once. They’ve only targeted one at a time.

Cytonics may have cracked the code.

Founded by Stanford-trained surgeon Dr. Gaetano Scuderi, they made a discovery Big Pharma missed entirely: The human body already produces a protein that neutralizes the enzymes destroying cartilage. It just doesn't produce enough of it where it's needed most.

So Cytonics harnessed it and their first-generation therapy has already treated 10,000+ patients. Now they've engineered a 200% more potent, mass-producible version pushing toward FDA approval. It’s a long-needed therapy designed to halt cartilage destruction and stimulate repair at the molecular level.

But that's only scratching the surface of why 7,000+ investors have already backed Cytonics. This is your chance to join them before this opportunity ends later this month.

• Breakthrough: If approved, Cytonics treatment could be the first true disease-modifying treatment for osteoarthritis in history.
• Traction: With a Phase 1 human safety trial completed with zero adverse events, Cytonics has the clinical proof to back their science. If approved, the more than 500M osteoarthritis patients worldwide* could have their long-needed solution.
• Proven Support: $32M of capital raised to date, including a seven-figure investment from pro athletes Rener and Eve Gracie, backed by partnerships with Stanford and Scripps Research.
• Opportunity: Until later this month, everyday investors have the limited-time chance to participate in an early-stage biotech investment opportunity that’s historically been reserved for VCs and institutional investors.

Historically, Big Pharma has made its move on biotech targets near this point, when efficacy data exists but a price hasn't been set. 

Merck acquired Prometheus for $10.8B. GSK acquired Bellus for $2B. While nothing's guaranteed, Cytonics is now preparing for that critical phase of value creation.

And unlike prior decades, where early-stage biotech investing was reserved exclusively for venture capital and institutional investors, you can claim a stake in Cytonics today. But you don’t have long to act.

This is your chance to back the company creating the first therapy with the potential to actually address the root cause of osteoarthritis at the molecular level. 

Cytonics aims to win one of the biggest opportunities in medicine. Don’t miss out. Invest before this month’s deadline.

This is a paid advertisement for Cytonic's Regulation CF offering. Please read the offering circular and related risks at invest.cytonics.com/. Barchart has not reviewed, approved, or endorsed the content and was paid $3.00 per click for placement and promotion of the content on this site and other forms of public distribution covering the period of July-August 2026. Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal